Table 1.
The relationship between CD33+ MDSCs, PD-1−PD-L1+ B cells, and clinicopathologic features of the patients.
| Variables | All cases | CD33+ MDSCs | P value | PD-1−PD-L1+CD19+ B cells | P value | ||
|---|---|---|---|---|---|---|---|
| Low | High | Low | High | ||||
| Age | |||||||
| <50 years | 42 | 21 (50.0%) | 21 (50.0%) | 0.090 | 18 (42.9%) | 24 (57.1%) | 0.061 |
| ≥50 years | 41 | 28 (68.3%) | 13 (31.7%) | 26 (63.4%) | 15 (36.6%) | ||
| LN metastasis | |||||||
| Yes | 41 | 25 (61.0%) | 16 (39.0%) | 0.723 | 23 (56.1%) | 18 (43.9%) | 0.578 |
| No | 42 | 24 (57.1%) | 18 (42.9%) | 21 (50%) | 21 (50%) | ||
| TNM stage | |||||||
| I | 27 | 16 (59.3%) | 11 (40.7%) | 0.875 | 15 (55.6%) | 12 (44.4%) | 0.536 |
| II | 41 | 25 (61.0%) | 16 (39.0%) | 23 (56.1%) | 18 (43.9%) | ||
| III | 15 | 8 (53.3%) | 7 (46.7%) | 6 (40%) | 9 (60%) | ||
| ER | |||||||
| Positive | 56 | 39 (69.6%) | 17 (30.4%) | 0.005 | 29 (51.8%) | 27 (48.2%) | 0.747 |
| Negative | 27 | 10 (37.0%) | 17 (63.0%) | 15 (55.6%) | 12 (44.4%) | ||
| PR | |||||||
| Positive | 46 | 31 (67.4%) | 15 (32.6%) | 0.084 | 26 (56.5%) | 20 (43.5%) | 0.475 |
| Negative | 37 | 18 (48.6%) | 19 (51.4%) | 18 (48.6%) | 19 (51.4%) | ||
| HER2 | |||||||
| Positive | 42 | 26 (61.9%) | 16 (38.1%) | 0.591 | 21 (50%) | 21 (50%) | 0.578 |
| Negative | 41 | 23 (56.1%) | 18 (43.9%) | 23 (56.1%) | 18 (43.9%) | ||